Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07453368Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of orelabrutinib in autoimmune hemolytic anemia (AIHA) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate at 12 weeks. Started Mar 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07453368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07453368.